Hosted on MSN24m
23andMe to cut 40% of workforce, end therapeutics program23andMe went public in 2021 and grew to a market valuation of $6 billion. Since April, Wojcicki had been trying to take the ...
Holding “announced a business restructuring to streamline operations and reduce costs. In addition, 23andMe is discontinuing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback